Portfolio (Quarterly)
Guide ↗
Aisling Capital Management LP
· CIK 0001766721| # | Ticker | Company | Sector | Shares | Value ↓ | % Port | Chg Shares | Chg % | Period Price ① | Since Period ① |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | GLUE | Monte Rosa Therapeutics Inc (GLUE) | Healthcare | 1,555,664.0 | $25.6M | 5.37% | +83K | +5.7% | $16.45 | +11.3% |
| 2 | — | BridgeBio Oncology Therapeutics (BBOT) | — | 1,018,018.0 | $9.1M | 1.91% | +453K | +80.3% | $8.95 | — |
| 3 | CMPS | Compass Pathways Plc (CMPS) | Healthcare | 1,432,336.0 | $7.9M | 1.66% | +234K | +19.5% | $5.53 | +126.6% |
① Period Price is the implied market price on the last day of the reporting period, calculated as reported value ÷ shares held. It is not the fund's purchase price or cost basis — the fund may have initiated or added to the position at any point during the quarter at a different price. Since Period shows the price change from that quarter-end snapshot to today's last price — it reflects stock movement after the report date, not the fund's actual return.
Sector Allocation
Healthcare
100.0%